Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financi...(erior pharmacokinetic properties and eve...),Health

                                 ARDEA BIOSCIENCES, INC.

                    Condensed Consolidated Statements of Operations
                                      (Unaudited)
                       (in thousands, except per share amounts)


                                      Three Months Ended     Nine Months Ended
                                         September 30,         September 30,
                                      ------------------     -----------------
                                        2009       2008       2009       2008
                                        ----       ----       ----       ----
    Revenues:
        License fees                  $8,178         $-    $13,191         $-
        Sponsored research                 -          -          -        260
        Reimbursable research and
         development expenses            991          -      1,490          -
                                       -----      -----      -----      -----
          Total revenues               9,169          -     14,681        260

    Operating expenses:
      Research and development         8,999     11,459     30,720     34,351
      General and administrative       2,404      3,043      7,807      9,723
                                       -----      -----      -----      -----
          Total operating expenses    11,403     14,502     38,527     44,074

    Loss from operations              (2,234)   (14,502)   (23,846)   (43,814)

    Other income (expense):
      Interest income                     65        293        320      1,314
      Interest expense                  (320)       (10)    (1,032)       (11)
      Other income, net                   18         (4)        21        182
                                   
'/>"/>
SOURCE  Ardea Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
2. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
3. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
4. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
7. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
8. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
11. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load